Exploratory metabolic implications of particle size

Lead Researcher:


Research Team:Status: Active


  • Teva
  • Research in Real Life


Short Description:

Aim to assess metabolic and other adverse consequences of small particle ICS and large particle ICS in relation to their clinical benefits in patients with obstructive lung disease. Objectives include to examine worsening control of pre-existing diabetes, risk of developing new-onset diabetes, change in BMI (where sufficient data are available) and incidence of LRTIs, determining absolute rate and any dose-response relationship. Worsening diabetic control will be compared with the number of exacerbations for both treatments in order to provide an overall risk-benefit assessment.

Documents and Publications




Final Publications

Additional Material